RECURRENT WHO GRADE III GLIOMA
Clinical trials for RECURRENT WHO GRADE III GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE III GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE III GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at deadly brain cancer
Disease control OngoingThis early-phase trial is testing a new type of personalized immunotherapy for patients with malignant brain tumors (gliomas) that have returned or stopped responding to standard treatments. Doctors collect a patient's own immune cells (T-cells), genetically modify them in a lab …
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New immune cell therapy tested for aggressive brain tumors
Disease control OngoingThis is an early-stage safety study for a new type of CAR T-cell therapy designed for adults with a specific type of recurrent brain cancer called glioblastoma. The main goals are to find the safest dose and understand the side effects. Doctors will collect a patient's own immune…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Modified stem cells sent to fight brain cancer
Disease control OngoingThis early-stage study is testing the safety of a new two-part treatment for aggressive brain tumors that have returned after standard therapy. Doctors place genetically modified stem cells directly into the brain during surgery, hoping these cells will make the tumor more sensit…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC
-
New hope for young brain cancer patients in Early-Stage trial
Disease control OngoingThis early-stage study is testing a new two-drug combination (BGB-290 and temozolomide) for adolescents and young adults with specific types of brain tumors that have returned or are newly diagnosed. The main goal is to find the safest dose and understand the side effects. Resear…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC